For more information:
Email UsComparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention
A PCORI Funding Announcement (PFA) will open on May 2, 2023 to fund studies that compare the effectiveness of pharmacologic and/or non-pharmacologic interventions that address migraine prevention.
Question of Interest
What is the comparative effectiveness of novel pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine?
Population
Individuals who suffer from migraines. Subgroups of particular interest include patients for whom prior preventive treatments have failed; patients with comorbidities including cardiovascular disease; various migraine types (medication overuse, episodic/chronic migraine, migraine with aura); and menstrual-associated migraine.
Interventions/Comparators
Head-to-head comparisons of evidence-based interventions that target migraine prevention.
Outcomes
Frequency, severity, and duration of migraine attacks, functional impairment, quality of life, adverse events, health resource utilization, relevant caregiver outcomes, and related outcomes.
Funding
- Total allocated for this PFA: Up to $40 million (not inclusive of intervention cost coverage)
- Total direct funding: $10 million (not inclusive of intervention cost coverage)
Maximum project duration
Five years.
Important dates
May 2 – Applications open
May 16 – Town Hall
May 31 – Letters of Intent due
August 29 – Applications due
November 2023 – Merit review
March 2024 – Awards announced
July 2024 – Earliest start date
For more information or to request a brief consultation, please contact Leslie MacGregor, PCORI Funding Specialist: Leslie_MacGregor@hms.harvard.edu